Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Khiron Life Sciences Corp. (V:KHRN)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 100 King St.W.
Suite 1600, 1 First Canadian Place
Tel: N/A
IR: See website
Key People
Alvaro Torres
Interim Chairman of the Board, Chief Executive Officer
Chris Naprawa
Darren Collins
Chief Financial Officer, Corporate Secretary
Wendy Kaufman
Chief Financial Officer
Business Overview
Khiron Life Sciences Corp, formerly Adent Capital Corp, is a Canada-based company engaged in alternative medicine sector. The Company is an integrated medical cannabis company with its core operations in Latin America. Khiron is active in the research area in medical cannabis industry. It develops and commercializes medical cannabis products mainly in Colombia.
Financial Overview
For the nine months ended 30 September 2019, Khiron Life Sciences Corp revenues increased from C$0K to C$7.1M. Net loss increased from C$13.3M to C$29.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative costs increase from C$6.6M to C$13.3M (expense), Share-based compensation increase from C$2.2M to C$7.1M (expense), Selling.
Reporting Currency: Canadian Dollars
Enterprise value: $103.66M as of Sep 30, 2019
Annual revenue (TTM): $7.96M as of Sep 30, 2019
EBITDA (TTM): -$34.88M as of Sep 30, 2019
Net annual income (TTM): -$35.77M as of Sep 30, 2019
Free cash flow (TTM): -$31.26M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 116,612,318 as of Dec 12, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization